Effect and safety of albumin-paclitaxel combined with sintilimab in the treatment of stage Ⅲb-Ⅳ gastric cancer patients with human epidermal growth factor receptor 2 negative
Objective To investigate the effect and safety of albumin-paclitaxel combined with sintilimab in the treat-ment of stage Ⅲb-Ⅳ gastric cancer patients with human epidermal growth factor receptor 2(HER2)negative.Method A total of 80 patients with HER2 negative Ⅲb-Ⅳ gastric cancer were divided into observation group(n=40,albumin-pa-clitaxel combined with sintilimab)and control group(n=40,albumin-paclitaxel)according to different treatment methods.The clinical efficacy,tumor marker[α-fetal protein(AFP),carbohydrate antigen(CA)72-4],functional status[Karnofsky performance status(KPS)score],quality of life[European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)],incidence of adverse reactions and progression-free survival were com-pared between two groups.Result The total effective rate in two groups was compared,and the difference was not statis-tically significant(P＞0.05).The disease control rate in observation group was higher than that in control group,the pro-gression-free survival time was longer than that in control group,and the differences were statistically significant(P＜0.05).After treatment,AFP and CA72-4 levels in two groups were lower than those before treatment,KPS and EORTC QLQ-C30 scores were higher than those before treatment,AFP and CA72-4 levels in observation group were lower than those in control group,KPS and EORTC QLQ-C30 scores were higher than those in control group,and the differences were statistically significant(P＜0.05).The incidence rates of fatigue,hypertension,proteinuria and abnormal liver func-tion in observation group were higher than those in control group,and the differences were statistically significant(P＜0.05).Conclusion Albumin-paclitaxel combined with sintilimab in the treatment of stage Ⅲb-Ⅳ gastric cancer patients with HER2 negative has good clinical efficacy,which can effectively reduce the level of serum tumor markers,improve the functional status and quality of life of patients,and extend the progression-free survival.However,it will increase the incidence of some adverse reactions.Therefore,it is necessary to pay more attention to adverse reactions,prevent in ad-vance and deal with in time.
human epidermal growth factor receptor 2gastric canceralbumin-paclitaxelsintilimab
万方数据
维普
